A Tat Fusion Protein–Based Tumor Vaccine for Breast Cancer
- 109 Downloads
We recently reported that dendritic cells (DCs) transduced with a fusion protein between Her2/neu and the protein transduction domain Tat (DC-Tat-extracellular domain [ECD]) induced Her2/neu-specific CD8+ T cells in vitro. This study tested the in vivo efficacy of DC-Tat-ECD in a murine breast cancer model.
FVB/N mice received one or two weekly intraperitoneal immunizations with syngeneic DC-Tat-ECD followed by a tumor challenge with syngeneic neu+ breast cancer cells, and tumor development was monitored. To test for Her2/neu specificity, CD4+ and CD8+ cells were isolated through magnetic bead separation and analyzed for specific interferon γ release.
Intraperitoneally injected DCs migrated to secondary lymphoid organs, as evidenced by small-animal positron emission tomography studies. Immunized mice developed palpable tumors significantly later than control mice injected with DC-Tat-empty (P = .001 and P < .05 for two immunizations and for one immunization, respectively) or mice that received no DCs (P = .001 and P < .05). Similarly, immunized mice had smaller resulting tumors than mice injected with DC-Tat-empty (P < .05 and P < .01) or untreated mice (P < .001 and P < .001). Significantly more tumor-specific CD8+ splenocytes were found in twice-immunized mice than in untreated animals (P < .001). Similarly, a T-helper type 1 CD4+ T-cell response was observed.
Protein-transduced DCs may be effective vaccines for the treatment of cancer.
KeywordsTat fusion protein Her2/neu Cancer vaccine Breast cancer Animal study
- 5.Schwarze, SR, Hruska, KA, Dowdy, SF 2000Protein transduction: unrestricted delivery into all cells?Trends Cell Biol 102905Google Scholar
- 14.Viehl CT, Tanaka Y, Chen T et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammoglobin-specific CD4 and CD8 T cells Breast Cancer Res Treat 2005, DOI: 10.1007/s10549-005-0450-4 Google Scholar
- 19.Yoshino, I, Goedegebuure, PS, Peoples, GE, et al. 1994HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancerCancer Res54338790Google Scholar
- 21.Tanaka, Y, Amos, KD, Joo, HG, Eberlein, TJ, Goedegebuure, PS 2001Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytesInt J Cancer945404Google Scholar
- 23.Kobayashi, H, Wood, M, Song, Y, Appella, E, Celis, E 2000Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigenCancer Res60522836Google Scholar
- 24.Reilly, RT, Gottlieb, MB, Ercolini, AM, et al. 2000HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceCancer Res60356976Google Scholar
- 32.Janik, P, Briand, P, Hartmann, NR 1975The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumorsCancer Res353698704Google Scholar
- 38.Viehl, CT, Liyanage, UK, Moore, TT, et al. 2004Depletion of regulatory T cells promotes a tumor-specific immune responseAnn Surg Oncol11S69Google Scholar
- 39.Wei, WZ, Shi, WP, Galy, A, et al. 1999Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNAInt J Cancer8174854Google Scholar